|
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet
Expects to qualify for 180 days of marketing exclusivity for multiple strengths PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- MylanInc. (NASDAQ:MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug...
|
|
|
Indian pharma Lupin gets US FDA OK for hypertension drug
Indian drug maker LUPIN LTD (BSE:500257) said Monday it has received final approval from the US drug regulator for marketing Amlodipine-Benazepril capsules, used for treating high blood pressure, in America.Indian pharma Lupin gets US FDA OK for...
|
|
|
INDIA'S LUPIN GETS US FDA OK TO MARKET BLOOD PRESSURE CAPSULES
Drug maker Lupin Ltd (BSE:500257) said Monday it has received final approval from the US drug regulator for marketing Amlodipine-Benazepril capsules, used for treating high blood pressure, in America.INDIA'S LUPIN GETS US FDA OK TO MARKET BLOOD...
|
|
|
Lupin gets US FDA approval to market blood pressure capsules
Mumbai: Drug maker Lupin Ltd on Monday said it has received final approval from the US drug regulator for marketing Amlodipine-Benazepril capsules, used for treating high blood pressure, in America.The company has received a final approval from the US...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet
Mylan Inc.has confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet
Mylan Inc.confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, 5...
|
|
|
Mylan first to file ANDA patent for Caduet Tablets
Mylan Inc.(Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine Besylate and Atorvastatin Calcium Tablets 2...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
Mylan Inc.(Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine Besylate and Atorvastatin Calcium Tablets 2...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
Expects to qualify for 180 days of marketing exclusivity for multiple strengths PR Newswire PITTSBURGH, Feb.4 PITTSBURGH, Feb. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
Companies mentioned in this article: Mylan Inc.PITTSBURGH, Feb. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S.
|
|
|
Mylan Confirms Pfizer Lawsuit Against Filing Of ANDA For Generic Caduet Tablets - Quick Facts
(RTTNews) - Mylan Inc.(MYL: News ) confirmed that it was sued by Pfizer (PFE: News ) in connection with the filing of an Abbreviated New Drug Application with the FDA for Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
PITTSBURGH, Feb.4 PITTSBURGH, Feb. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration ...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(...
Company: Mylan Inc/PA (MYL) Mylan Inc.(Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine Besylate and...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
Author : Mylan Inc.Category : Press Release News Alerts by Email ( click here ) News | Home PITTSBURGH, Feb. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated...
|
|
|
Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
Mylan Inc.(Nasdaq: MYL) today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine Besylate and Atorvastatin Calcium Tablets 2...
|
